KITE - Kite Pharma, Inc.

NasdaqGM - NasdaqGM Delayed price. Currency in USD
179.79
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close179.79
Open179.82
Bid0.00 x 0
Ask0.00 x 0
Day's range179.55 - 179.95
52-week range39.82 - 179.95
Volume100
Avg. volume1,943,910
Market cap10.31B
Beta2.47
PE ratio (TTM)-25.85
EPS (TTM)-6.95
Earnings date7 Nov 2017 - 13 Nov 2017
Forward Dividend & YieldN/A (N/A)
Ex-dividend dateN/A
1y target est156.56
Trade prices are not sourced from all markets
  • Barrons.com9 hours ago

    Gilead: Congratulations…But You Still Overpaid for Kite

    Less than two months ago, Gilead Sciences (GILD) announced an almost $12 billion deal to buy Kite Pharma. Late yesterday, the FDA approved Kite’s CAR-T cancer therapy for adults with advanced lymphoma. It uses genetically-engineered T-cells to attack cancer cells, and it is only the second such therapy to make it through the FDA.

  • The Wall Street Journal19 hours ago

    Gilead Gets FDA Approval for New Cancer Therapy

    Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.

  • Market Realist2 days ago

    Gilead Sciences on the Street: Analyst Recommendations in October

    Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."

  • 6 Top Biotech Companies In Innovation Earn Recognition In New Awards
    Investor's Business Daily3 days ago

    6 Top Biotech Companies In Innovation Earn Recognition In New Awards

    Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?

  • Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field
    Investor's Business Daily3 days ago

    Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field

    Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.

  • The 5 Best M&A Deals of 2017 (So Far!)
    Zacks16 days ago

    The 5 Best M&A Deals of 2017 (So Far!)

    Over the past few years, consolidation has become an important trend in nearly every major global industry. To celebrate this, we've compiled our list of the most important M&As of 2017!

  • Business Wire16 days ago

    Gilead Sciences Completes Acquisition of Kite Pharma, Inc.

    Gilead Sciences, Inc. today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead , to acquire Kite Pharma, Inc.

  • Business Wire16 days ago

    Gilead Sciences Completes Acquisition of Kite Pharma, Inc.

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead (“Purchaser”), to acquire Kite Pharma, Inc. (Nasdaq: KITE) for $180 per share, net to the seller in cash, without interest, or approximately $11.9 billion in the aggregate. On August 28, 2017, Gilead and Kite announced that Kite, Gilead and Purchaser had signed a definitive merger agreement pursuant to which a tender offer would be made.

  • Business Wire16 days ago

    Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc.

    Gilead Sciences, Inc. today announced the successful completion of the tender offer by its wholly-owned subsidiary, Dodgers Merger Sub, Inc. , for all of the outstanding shares of common stock of Kite Pharma, Inc.

  • Business Wire16 days ago

    Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc.

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of the tender offer by its wholly-owned subsidiary, Dodgers Merger Sub, Inc. (“Purchaser”), for all of the outstanding shares of common stock of Kite Pharma, Inc. (Nasdaq: KITE) at a price of $180 per share, net to the seller in cash, without interest. Computershare Trust Company, N.A., the depositary for the tender offer, has advised Gilead that, as of one minute after 11:59 p.m., New York City time, on October 2, 2017, the initial expiration of the tender offer, approximately 38,324,617 shares were validly tendered and not withdrawn in the tender offer, representing approximately 66.20% of Kite’s currently outstanding shares (including 2,003,002 shares delivered through Notices of Guaranteed Delivery, representing approximately 3.46% of the shares outstanding).

  • Barrons.com17 days ago

    Bluebird Bio: So Much for That Gilead Boost

    When Gilead Sciences (GILD) announced its acquisition of Kite Pharma (KITE), every company that had exposure to CAR-T --a type of cancer therapy that could allow for the creation of personalized drugs--got ...

  • Here's Why Bluebird Bio (BLUE) Stock Is Falling Today
    Zacks17 days ago

    Here's Why Bluebird Bio (BLUE) Stock Is Falling Today

    Shares of Bluebird Bio (BLUE), a major player in the emerging gene therapy and CAR-T research markets, slumped more than 6% in morning trading Monday after receiving a key analyst downgrade.

  • Two patients show the promise of a historic treatment, with an equally historic price tag
    CNBC20 days ago

    Two patients show the promise of a historic treatment, with an equally historic price tag

    Kymriah is among a new wave of therapies that use a patient's own cells as medicine. But this historic treatment comes with a historic price.

  • Business Wire23 days ago

    Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period

    Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offer for Kite expired at 11:59 p.m. on September 25, 2017. On September 8, 2017, Gilead and Kite filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice. With the expiration of the waiting period, the tender offer is expected to close in the beginning of October 2017, subject to customary closing conditions.

  • CNBClast month

    This year’s best-performing ETF could rise even higher

    Biotech stocks have been on a bionic run. Here's what's driving the move.

  • Reuters - UK Focus2 months ago

    Profit on $475,000 Novartis cancer drug could be a while coming

    Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even. In a first for gene therapy in the United States, regulators approved Kymriah on Wednesday for patients up to 25 years of age who have relapsed or not been helped by previous treatment for B-cell acute lymphoblastic leukemia (ALL). While patient groups hailed the potent immunotherapy as a potential cancer game-changer, the Swiss drugmaker was also criticised for setting a price that places Kymriah among the most-expensive drugs ever.

  • Investors are betting on a cancer cure with these stocks
    CNBC2 months ago

    Investors are betting on a cancer cure with these stocks

    U.S. regulators this week approved the first drug for a new type of cancer treatment, confirming a theme some stock pickers have found in biotech.

  • CNBC2 months ago

    Cramer pinpoints the trend that could lead to a surge in takeovers

    Jim Cramer says the market's response to some recent takeovers bodes well for the acquisition market going forward.

  • CNBC2 months ago

    Cramer: Why Apple matters more to the market than Hurricane Harvey

    Jim Cramer explains why a report on Apple's September 12 product meeting ignited a larger trading theme than Hurricane Harvey's aftermath.

  • Euro rises on bets for ECB tightening
    AFP2 months ago

    Euro rises on bets for ECB tightening

    The euro has been gaining against the dollar despite ECB chief Mario Draghi making no comments about monetary policy at a key meeting of central bankers last week.

  • Gilead buys $12 bn Kite to fly into cell therapy
    AFP2 months ago

    Gilead buys $12 bn Kite to fly into cell therapy

    Gilead Sciences said that it was paying $11.9 billion to acquire Kite Pharma, a firm which could soon have the first cell therapies available to sufferers of certain types of cancers

  • Business Wire2 months ago

    Gilead Sciences to Acquire Kite Pharma for $11.9 Billion

    Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter.

  • CNBC2 months ago

    Gilead to buy Kite Pharma for about $11 billion in cash: Dow Jones

    Gilead Sciences on Monday agreed to buy Kite Pharma for about $11 billion in cash, Dow Jones reported, citing sources.

  • CNBC2 months ago

    Cramer's lightning round: Here's the real reason behind Bank of America's decline

    Jim Cramer flies through his take on callers' favorite stocks, including one interest-rate-bound play.

  • Business Wire2 months ago

    Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union

    Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that patients in the European Union (EU) are now being treated with its lead investigational candidate, axicabtagene ciloleucel, in the safety expansion cohort of ZUMA-1 (ClinicalTrials.gov, NCT: 02348216). Kite is currently enrolling adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL) at multiple EU medical centers.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes